PET developer Compañía Mexicana de Radiología (CMR) Naviscan has signed an exclusive licensing and commercialization agreement with the Mayo Clinic for the molecular breast imaging (MBI) technologies used in the LumaGem MBI system.
The licensed MBI intellectual property was invented by a team of Mayo physicians and scientists, led by Michael O'Conner, PhD. CMR Naviscan acquired the LumaGem MBI system from molecular breast imaging developer Gamma Medica in October 2017 and now manufactures and distributes the system.
CMR Naviscan is positioning the LumaGem MBI system as a unit that improves cancer detection in women with dense breast tissue, with a lower risk for false positives than other imaging technologies such as MRI and whole-breast ultrasound.
